Company Profile

**Industry Sector:** Life Science research tools and services for cloning, amplification and NextGen DNA sequencing

**Company Overview:** Founded in 1998, Lucigen, a 26-person corporation, develops life science research products and technologies for gene cloning, amplification, genomics, and protein expression, which have been used successfully by academic and industrial researchers worldwide. Patented CloneSmart® technology and BigEasy® Cloning Kits dramatically improve DNA cloning reliability and efficiency, allowing successful capture of genes that have been impossible to clone using standard methods. Lucigen’s Services, including our exclusive Random Shear BAC Library Cloning Service, are being used by genome researchers to accelerate DNA sequencing and screening projects, saving time and research dollars.

**Targeted Market(s):** Academic and pharmaceutical genomic research laboratories worldwide.

Key Value Drivers

**Technology:** ExCyto® Sequencing technology utilizes novel fusion DNA polymerases that have been optimized for processivity and fidelity, which have been incorporated directly into the bacterial chromosome. Competent bacterial cells containing the polymerase are available for direct PCR and DNA sequencing.

**Competitive Advantage:** ExCyto® competent cells dramatically reduce DNA amplification and sequencing costs.

Plan & Strategy: Sell amplification products direct through our current and growing (+24% ’09) PCR business, seeking a strategic partner to integrate market-ready sequencing tool.

*Technology funded by the NHGRI and being commercialized under the NIH-CAP

Management

**Leadership:** David Mead, PhD, Founder & CEO, Lucigen is David’s 2nd company having successfully sold his first start-up, has also held senior research positions at Promega and Bio-Rad.

Jeffrey Williams, PhD, President, over 20 years of executive level management at companies such as Promega, Roche Molecular Systems/Applied Science and Ambion.

Thomas Schoenfeld, Vice President Enzyme Discovery
Vinay Dhodda, PhD, Vice President Manufacturing
Chengcang Wu, PhD, Vice President Custom Services
Thomas Carney, Controller

**Board of Directors:** Ralph Kauten, (Chairman), CEO of Quintessence Biosciences, a biotechnology company developing new cancer therapeutics.

Chris Fortune, President and CEO of SARIS Cycling Group, a developer and manufacturer of cycling equipment.

Tim Konicek, Director of Venture Investments for CleanTech Partners, a private, non-profit organization that invests in emerging, energy-saving technologies.

Product Pipeline

<table>
<thead>
<tr>
<th>ExCyto® Products</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fusion DNA Polymerases</td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
</tr>
<tr>
<td>Competent Cells</td>
<td>Q1</td>
<td>Q2</td>
<td>Q3</td>
</tr>
</tbody>
</table>

**Strategic Partnership**

Generate Supporting Data
Identify Potential Partners
Finalize Partnership